Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page # {* I! f" O; }
|" Y' g6 E! [' l& j/ m% E% G3 i1 e5 C* s( o$ v6 J3 \. ]
Sub-category:! ]2 R+ Y' }; d4 _
Molecular Targets
6 a% v* q4 `- H3 Q4 h, |1 J4 @3 q& D
3 }/ T4 s8 u' H& w! n2 I
, C$ O% n% c& T& i' t- v: cCategory:
, _+ f3 z: U2 ]8 v7 wTumor Biology 9 R2 c k( O0 Z5 r1 o% R
! M0 Q/ I1 ?4 u& I) m
J* |4 P" s5 e2 N2 | ]4 p: y
Meeting:% ^" y- h# l7 E, W
2011 ASCO Annual Meeting + h- `( }8 D7 f* J
$ H. w' q8 ?0 ]- K4 N( N& F$ E
6 p' G- }7 t: H- z
Session Type and Session Title:7 O+ _9 @/ t* X2 x2 \
Poster Discussion Session, Tumor Biology & q" f2 Q/ X8 j ~) t) ]# |4 u
0 ?! A% ?8 E% J& g: z
: ]2 d- _% D. q0 s/ aAbstract No:
* w" w; K) u4 [8 M3 h10517
/ }0 Z% b5 o; M* a
2 q3 R1 h- \7 h, n( ]; O3 D& r3 `. Z, P- W, S7 m
Citation:
% s1 ]7 S8 f/ h8 XJ Clin Oncol 29: 2011 (suppl; abstr 10517)
% m: z2 G9 ^( c1 F' |* i) H& }8 w: l) Y) B
$ A/ I! ]$ X) V4 D: J+ W# ?! xAuthor(s):. z" U5 Q# S" A" F+ K' i4 E0 ?- s
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 E# q4 \0 w6 K, o4 D& `+ L1 _
F& ^' N3 \- t( ]) z+ \
9 l6 }9 X8 D- K( n" R" o* b# J |- U$ V" V+ W: e9 d, j( R3 k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
4 \, P: n1 l& v5 R( B" Y# A) q1 J8 l, S t" ~( I! q2 d! R
Abstract Disclosures1 S3 Y$ ]7 t, u6 ]1 Q# ~& _
7 b% t' k; H$ B& h6 `. N- U4 i
Abstract:5 J8 c$ l6 o6 T
" _. @# }4 }! ?
5 j4 s! e( |$ K' @* u- ABackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
( ?7 c. k# v, H: \% l- J
1 z- A9 ?, c% a# X% ^# v $ ^) ^2 P$ r' b* \" u- O& J
|